Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 671281, 9 pages
http://dx.doi.org/10.1155/2013/671281
Research Article

Ixeris dentata NAKAI Reduces Clinical Score and HIF-1 Expression in Experimental Colitis in Mice

1Department of Oriental Pharmacy, College of Pharmacy, Wonkwang-Oriental Medicines Research Institute, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea
2Department of Pharmacology, College of Korean Medicine, Institute of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, Republic of Korea
3Department of Anatomy and Histology, College of Oriental Medicine, Daegu Hanny University, Yugok-Dong, Kyungsan 712-715, Republic of Korea
4Department of Cosmeceutical Science, Daegu Hanny University, Yugok-Dong, Kyungsan 712-715, Republic of Korea
5Isotope Sciences Lab, Korea Atomic Energy Research Institute, 1266 Shinjeong-dong, Jeongeup, Jeonbuk 580-185, Republic of Korea
6Department of Medicinal Herb, Gyeongju University, Gyeongbuk 780-712, Republic of Korea
7Department of Biochemistry, School of Medicine, Wonkwang University, Iksan, Chonbuk 570-749, Republic of Korea
8Department of Herbology, College of Oriental Medicine, Wonkwang University, Iksan 570-749, Republic of Korea

Received 2 April 2013; Accepted 7 August 2013

Academic Editor: Seong-Gyu Ko

Copyright © 2013 Dae-Seung Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Li, C. de Haar, M. Chen et al., “Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis,” Gut, vol. 59, no. 2, pp. 227–235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Ogata and T. Hibi, “Cytokine and anti-cytokine therapies for inflammatory bowel disease,” Current Pharmaceutical Design, vol. 9, no. 14, pp. 1107–1113, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. K. A. Papadakis and S. R. Targan, “Role of cytokines in the pathogenesis of inflammatory bowel disease,” Annual Review of Medicine, vol. 51, pp. 289–298, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Mueller, “Tumour necrosis factor in mouse models of chronic intestinal inflammation,” Immunology, vol. 105, no. 1, pp. 1–8, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. McCartney, J. A. Mitchell, P. D. Fairclough, M. J. G. Farthing, and T. D. Warner, “Selective COX-2 inhibitors and human inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 8, pp. 1115–1117, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. P. J. Roberts, K. Morgan, R. Miller, J. O. Hunter, and S. J. Middleton, “Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease,” Gut, vol. 48, no. 4, pp. 468–472, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. S. N. Agoff, T. A. Brentnall, D. A. Crispin et al., “The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia,” American Journal of Pathology, vol. 157, no. 3, pp. 737–745, 2000. View at Google Scholar · View at Scopus
  8. J. J. Haddad, “Science review: redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for hypoxia-inducible factor-1α,” Critical Care, vol. 7, no. 1, pp. 47–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. C. T. Taylor and S. P. Colgan, “Hypoxia and gastrointestinal disease,” Journal of Molecular Medicine, vol. 85, no. 12, pp. 1295–1300, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Jung, J. S. Isaacs, S. Lee, J. Trepel, and L. Neckers, “IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis,” The FASEB Journal, vol. 17, no. 14, pp. 2115–2117, 2003. View at Google Scholar · View at Scopus
  11. A. Robinson, S. Keely, J. Karhausen, M. E. Gerich, G. T. Furuta, and S. P. Colgan, “Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition,” Gastroenterology, vol. 134, no. 1, pp. 145–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Ahn, M. Bang, M. Song et al., “Cytotoxic and ACAT-inhibitory sesquiterpene lactones from the root of Ixeris dentata forma albiflora,” Archives of Pharmacal Research, vol. 29, no. 11, pp. 937–941, 2006. View at Google Scholar · View at Scopus
  13. S. H. Oh, T. H. Sung, and M. R. Kim, “Ixeris dentata extract maintains glutathione concentrations in mouse brain tissue under oxidative stress induced by kainic acid,” Journal of Medicinal Food, vol. 6, no. 4, pp. 353–358, 2003. View at Google Scholar · View at Scopus
  14. J. Yi, S. Hong, H. Lee et al., “Ixeris dentata green sap inhibits both compound 48/80-induced aanaphylaxis-like response and IgE-mediated anaphylactic response in murine model,” Biological & Pharmaceutical Bulletin, vol. 25, no. 1, pp. 5–9, 2002. View at Google Scholar · View at Scopus
  15. E. Park, J. Sung, H. Trinh et al., “Lactic acid bacterial fermentation increases the antiallergic effects of Ixeris dentata,” Journal of Microbiology and Biotechnology, vol. 18, no. 2, pp. 308–313, 2008. View at Google Scholar · View at Scopus
  16. R. S. Blumberg, L. J. Saubermann, and W. Strober, “Animal models of mucosal inflammation and their relation to human inflammatory bowel disease,” Current Opinion in Immunology, vol. 11, no. 6, pp. 648–656, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya, “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice,” Gastroenterology, vol. 98, no. 3, pp. 694–702, 1990. View at Google Scholar · View at Scopus
  18. B. A. Hendrickson, R. Gokhale, and J. H. Cho, “Clinical aspects and pathophysiology of inflammatory bowel disease,” Clinical Microbiology Reviews, vol. 15, no. 1, pp. 79–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. S. N. S. Murthy, H. S. Cooper, H. Shim, R. S. Shah, S. A. Ibrahim, and D. J. Sedergran, “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin,” Digestive Diseases and Sciences, vol. 38, no. 9, pp. 1722–1734, 1993. View at Google Scholar · View at Scopus
  20. S. Kim, M. Kim, J. Um, and S. Hong, “The beneficial effect of vanillic acid on ulcerative colitis,” Molecules, vol. 15, no. 10, pp. 7208–7217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Hamamoto, K. Maemura, I. Hirata, M. Murano, S. Sasaki, and K. Katsu, “Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (icam-1)),” Clinical and Experimental Immunology, vol. 117, no. 3, pp. 462–468, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ardizzone and G. B. Porro, “Biologic therapy for inflammatory bowel disease,” Drugs, vol. 65, no. 16, pp. 2253–2286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. P. A. Rufo and A. Bousvaros, “Current therapy of inflammatory bowel disease in children,” Pediatric Drugs, vol. 8, no. 5, pp. 279–302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Sato, S. Ohkura, Y. Kitahara et al., “Involvement of CPI-17 downregulation in the dysmotility of the colon from dextran sodium sulphate-induced experimental colitis in a mouse model,” Neurogastroenterology and Motility, vol. 19, no. 6, pp. 504–514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Ishiguro, T. Ohkawara, H. Sakuraba et al., “Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis,” Clinical Immunology, vol. 120, no. 3, pp. 335–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. W. J. Sandborn and S. R. Targan, “Biologic therapy of inflammatory bowel disease,” Gastroenterology, vol. 122, no. 6, pp. 1592–1608, 2002. View at Google Scholar · View at Scopus
  27. K. J. Myers, S. Murthy, A. Flanigan et al., “Antisense oligonucleotide blockade of tumor necrosis factorα in two murine models of colitis,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 1, pp. 411–424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Naito, T. Takagi, K. Uchiyama et al., “Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice,” International Journal of Molecular Medicine, vol. 14, no. 2, pp. 191–196, 2004. View at Google Scholar · View at Scopus
  29. F. Obermeier, G. Kojouharoff, W. Hans, J. Schölmerich, V. Gross, and W. Falk, “Interferon-gamma (IFN-γ)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice,” Clinical and Experimental Immunology, vol. 116, no. 2, pp. 238–245, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Fonseca-Camarillo, M. Villeda-Ramirez, F. Sanchez-Munoz et al., “IL-6 and TNF-a gene expression in the rectal mucosal of patients with chronic idiopathic ulcerative colitis and controls,” Revista de Gastroenterología de México, vol. 74, no. 4, pp. 334–340, 2009. View at Google Scholar
  31. I. Morita, “Distinct functions of COX-1 and COX-2,” Prostaglandins and other Lipid Mediators, vol. 68-69, pp. 165–175, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Okayama, S. Hayashi, Y. Aoi, H. Nishio, S. Kato, and K. Takeuchi, “Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats,” Digestive Diseases and Sciences, vol. 52, no. 9, pp. 2095–2103, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Brune and B. Hinz, “Selective cyclooxygenase-2 inhibitors: similarities and differences,” Scandinavian Journal of Rheumatology, vol. 33, no. 1, pp. 1–6, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. El-Medany, A. Mahgoub, A. Mustafa, M. Arafa, and M. Morsi, “The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats,” European Journal of Pharmacology, vol. 507, no. 1–3, pp. 291–299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Lauritsen, L. S. Laursen, J. Kjeldsen, K. Bukhave, T. K. Hansen, and J. Rask-Madsen, “Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products,” Advances in Experimental Medicine and Biology B, vol. 371, pp. 1301–1306, 1995. View at Google Scholar · View at Scopus
  36. J. Karhausen, G. T. Furuta, J. E. Tomaszewski, R. S. Johnson, S. P. Colgan, and V. H. Haase, “Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis,” The Journal of Clinical Investigation, vol. 114, no. 8, pp. 1098–1106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Giatromanolaki, E. Sivridis, C. Kouskoukis, K. C. Gatter, A. L. Harris, and M. I. Koukourakis, “Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin,” Melanoma Research, vol. 13, no. 5, pp. 493–501, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Mariani, P. Sena, L. Marzona et al., “Cyclooxygenase-2 and Hypoxia-Inducible factor-1α protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis,” Cancer Letters, vol. 279, no. 2, pp. 221–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Scortegagna, C. Cataisson, R. J. Martin et al., “HIF-1α regulates epithelial inflammation by cell autonomous NFκB activation and paracrine stromal remodeling,” Blood, vol. 111, no. 7, pp. 3343–3354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Agarwal, P. Swaroop, P. Protiva, S. V. Raj, H. Shirin, and P. R. Holt, “Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells,” Apoptosis, vol. 8, no. 6, pp. 649–654, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Zhong, M. Willard, and J. Simons, “NS398 reduces hypoxia-inducible factor (HIF)-1α and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms,” International Journal of Cancer, vol. 112, no. 4, pp. 585–595, 2004. View at Publisher · View at Google Scholar · View at Scopus